Q1 2027 Neogen Chemicals Ltd Earnings Call Transcript
Key Points
- Neogen Chemicals Ltd (BOM:542665) reported a robust 34% year-on-year revenue growth in Q1 FY27, reaching INR250 crores.
- The company's EBITDA grew by 53% year-on-year to INR48 crores, with margins expanding by 260 basis points to 19.3%.
- Neogen Ionics, a segment of the company, delivered a strong performance with INR19 crores in revenue, a significant increase from INR5 crores in Q1 FY26.
- The company has initiated cost pass-through mechanisms with customers to safeguard operating margins against raw material and input cost fluctuations.
- Neogen Chemicals Ltd (BOM:542665) has secured provisional approvals from four international customers for lithium electrolyte salts, indicating strong future demand.
- The global chemical industry is facing persistent geopolitical volatility and uneven end market demand, which could impact future performance.
- The company is experiencing elevated shipping freight costs and temporary overheads related to interim toll manufacturing arrangements.
- Finance costs increased by 64% due to higher debt drawdown for ongoing CapEx and increased working capital intensity.
- The Dahej plant rebuild and associated costs are impacting current financial performance, although it is expected to commence commercial production soon.
- There is uncertainty regarding the impact of changing battery technologies and potential restrictions from China on battery technology, which could affect growth projections.
Ladies and gentlemen, good day, and welcome to the Neogen Chemicals Limited Q1 FY27 earnings conference call. (Operator Instructions) I now hand the conference over to Mr. Nishid Solanki from CDR India. Thank you, and over to you, sir.
Thank you. Good afternoon, everyone, and welcome to Neogen Chemicals Q1 FY27 earnings conference call. Joining us today from the senior management team are Mr. Anurag Surana, Non-Executive Chairman; Dr. Harin Kanani, Managing Director; and Mr. Gopikrishnan Sarathy, Chief Financial Officer. We will begin the call with opening remarks from the management team followed by an interactive question-and-answer session.
Before we begin, a standard disclaimer. Certain statements made during today's call may be forward looking. Actual results could differ and a detailed disclaimer is available in our Q1 FY27 earnings presentation, which has been uploaded on stock exchange websites.
With that, I would now like to invite Dr. Harin Kanani to share his opening remarks. Thank you, and over
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
